Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Muscular Dystrophies
Lancet 394:2025-2038, Mercuri, E.,et al, 2019
Newer Agents in the Treatment of Multiple Sclerosis
Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Clinical Update:Diagnosis and Treatment of Essential Tremor
Lancet 369:1152-1154, Benito-Leon,J&Louis,E.D., 2007
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Adult Epilepsy
Lancet 367:1087-1100, Duncan,J.S.,et al, 2006
Ximelagatran--Promises and Concerns
JAMA 293:736-739, Gurewich,V., 2005
The New Antiepileptic Drugs, Scientific Review
JAMA 291:605-614, LaRoche,S.M.&Helmers,S.L., 2004
Management of Epilepsy in Adolescents and Adults
Lancet 356:323-329, Brodie,M.J. & French,J.A., 2000
Medical Management of Epilepsy in Adults
Neurol 51:S15-S20, Mattson,R.H., 1999
HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
New Antiepileptic Drugs
Arch Neurol 55:1181-1183, Bourgeois,B.F.D., 1998
Parkinson's Disease
NEJM 339:1044-1053,1130-1143, Lang,A.E.&Lozano,A.M., 1998
Parenteral Fosphenytoin:Efficacy and Economic Considerations
The Neurologist 4:S30-S34, Ramsay,R.E.&Wilder,B.J., 1998
New Antiepileptic Drugs
NEJM 334:1583-1590, Dichter,M.A.&Brodie,M.J., 1996
The Use of Parenteral Antiepileptic Drugs & The Role of Fosphenytoin
(Suppl Editor) , Neurol 46:S1-S2896., Wilder,B.J., 1996
New Antiepileptic Drugs:A Systematic Review of Their Efficacy and Tolerability
BMJ 313:1169-1174, 1157, 1158996., Marson,A.G.,et al, 1996
Commonly Used Interventional Procedures for Non-Cancer Chronic Spine Pain: A Clinical Practice Guideline
BMJ 388:e079970, Busse,J.W.,et al, 2025
The Role of GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists in Primary Stroke Prevention
Stroke 56:e307-e309, Inikori,E.,et al, 2025
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024
Neuroleptic Malignant Syndrome
NEJM 391:1130-1138, Wijdicks,E.F.M. & Ropper,A.H., 2024
Autoimmune Encephalitis Misdiagnosis in Adults
JAMA Neurol 80:30-39, Flanagan,E.P.,et al, 2023
Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
Cannabis-Related Disorders and Toxic Effects
NEJM 389: 2267-2275, Gorelick,D.A., 2023
Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Encephalitis Induced by Immune Checkpoint Inhibitors
JAMA Neurol 78:864-873, Velasco, R.,et al, 2021
Drugs Associated with Ischemic Stroke
Stroke 52:e646-e659, Marto, J.P.,et al, 2021
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Blurred Vision
BMJ 368:m569, Zhou, S.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Pregabalin and Gabapentin for Pain
BMJ 369:m1315, Mathieson, S.,et al, 2020
Deprescribing in Epilepsy
JAMA Neurol 77:673-674, Terman, S.W.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Acute Toxic Leukoencephalopathy: Etiologies, Imaging Findings, and Outcomes in 101 Patients
AJNR 40:267-275, Ozutemiz, C.,et al, 2019
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Clinical Characteristics and Outcomes of Methamphetamine-Associated Intracerebral Hemorrhage
Neurol 93:e1-e7, Swor, D.E.,et al, 2019
Toxoplasmosis in HIV-Infected Patients
www.UptoDate.com, May, Gandhi, R.T., 2019
Medical Use of Cannabis in 2019
JAMA 322:974-975, Hill, K.P., 2019
Reversible Cerebral Vasoconstriciton Syndrome
www.UptoDate.com, June, Singhal, A., 2019
Factor Xa Inhibitors Versus Vitamin K Antagonists for Prevention of Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Stroke 49:e235-e236, Bruins Slot, K.M.H. & Berge, E., 2018
Efficacy and Tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
Neurol 91:82-90, Kanner, A.M.,et al, 2018
Efficacy and Tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy
Neurol 91:74-81, Kanner, A.M.,et al, 2018